GlobeNewswire

Nexstim Abp meddelar om valberedningsbeslut

20.1.2021 08:30:00 CET | GlobeNewswire

Dela

Företagsmeddelande, Helsingfors 20 januari 2021 kl. 9.30 (EET)

Nexstim Abp meddelar om valberedningsbeslut

Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) meddelar om valberedningens beslut.

Rohan Hoare, som varit styrelseledamot i bolaget sedan 2016, och Tomas Holmberg, som varit styrelseledamot i bolaget sedan 2017, har meddelat att de inte står till förfogande för en fortsatt  styrelsepost i bolaget 2021–2022. Valberedningen har på sitt sammanträde beslutat att för årsstämman föreslå Timo Hildén och Tero Weckroth som nya styrelseledamöter.

Leena Niemistö, ordförande för Nexstims styrelse, lämnade följande kommentar: ”Det gläder mig verkligen att Timo Hildén och Tero Weckroth ställer upp för uppdrag i Nexstims styrelse. Bägge har gedigen och mångsidig erfarenhet inom medicintekniksektorn och läkemedelsindustrin. Timo Hildén har solid erfarenhet inom hälso- och medicintekniksektorn, såväl från den operativa verksamheten som i lednings- och styrelseuppdrag. Tero Weckroth är ett proffs inom läkemedelsindustrin och har dessutom arbetat länge med internationell finansiering. De är med andra ord utomordentligt väl lämpade för att hjälpa Nexstim växa till ett internationellt företag med stort genomslag. Samtidigt vill jag rikta ett varmt tack till Rohan Hoare och Tomas Holmberg för deras insatser i Nexstims styrelse. Jag önskar dem all lycka i framtiden.”

För mer information, gå in på bolagets webbplats på www.nexstim.com, eller kontakta:

Leena Niemistö, ordförande
+358 9 2727 170
leena.niemisto@nexstim.com

Erik Penser Bank AB (Certified Adviser)                         
 +46 8 463 83 00
certifiedadviser@penser.se

Om Nexstim Abp

Nexstim är ett finskt medicintekniskt företag med global verksamhet. Vår mission är att möjliggöra individanpassad och effektiv behandling och diagnostik av svåra sjukdomar och störningar i hjärnan.

Nexstim har tagit fram en världsledande teknik för icke-invasiv hjärnstimulering, kallad SmartFocus®. Tekniken som använder navigerad transkraniell magnetstimulering (nTMS) med avancerade 3D-navigering gör det möjligt att individanpassa TMS och nå exakt rätt del av hjärnan.

SmartFocus® används i Nexstims proprietära system för navigerad hjärnterapi (Navigated Brain Therapy, NBT®), som har beviljats tillstånd av FDA för marknadsföring och försäljning i USA för behandling av egentlig depression (MDD). I Europa har NBT®-systemet fått CE-märkning för behandling av egentlig depression och kronisk neuropatisk smärta.

Nexstim kommersialiserar också sitt SmartFocus®-baserade system för navigerad hjärnstimulering (Navigated Brain Stimulation, NBS). NBS-systemet är det enda FDA-godkända och CE-märkta TMS-systemet för preoperativ kartläggning av hjärnbarken för motorik och tal. Nexstims aktier är noterade på Nasdaq First North Growth Market Finland och Nasdaq First North Growth Market Sweden.

Mer information finns på www.nexstim.com

Bilaga


Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States4.3.2021 22:00:00 CET | Press release

► Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development ► Breakthrough Therapy Designation granted to lanifibranor in NASH by the U.S. Food and Drug Administration (FDA) ► Finalization of Phase III clinical trial design with lanifibranor in NASH following end-of-phase II meeting with the FDA and receipt of Scientific Advice letter from the European Medicines Agency (EMA) ► Expansion into the United States with appointment of Dr. Michael Cooreman, M.D., as Chief Medical Officer and opening of U.S. subsidiary ► Announcement of timeline for Phase III clinical trial evaluating lanifibranor in NASH ► Confirmation by the FDA that the toxicology package regarding lanifibranor is complete and acceptable to support the filing of a New Drug Application (NDA) for the treatment of NASH and improvement of liver fibrosis ► Completion of World Health Organization’s (WHO) International No

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report4.3.2021 22:00:00 CET | Press release

Nokia has filed its Annual Report on Form 20-F for 2020 and published its Nokia in 2020 Annual Report Nokia Corporation Stock Exchange Release March 4, 2021 at 23:00 EET Nokia has filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission and published its Nokia in 2020 Annual Report. Espoo, Finland – Nokia has today filed its Annual Report on Form 20-F for 2020 with the U.S. Securities and Exchange Commission. Additionally, Nokia has published its Nokia in 2020 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2020. The Annual Report on Form 20-F and Nokia in 2020 Annual Report will be available in PDF format at www.nokia.com/about-us/investors/reports-filings, along with Nokia’s past quarterly and annual financial reports. Shareholders may request a hard copy of the reports free of charge through Nok

Appellate Court Hands Momentous Victory to TriMax Over Wickfire4.3.2021 21:35:30 CET | Press release

The Fifth Circuit Court of Appeals issued a decisive ruling that TriMax Media committed no legal violations against Wickfire, L.L.C., while recognizing a jury’s finding that Wickfire intentionally interfered with TriMax’s business. DALLAS, March 04, 2021 (GLOBE NEWSWIRE) -- After seven years of litigation, TriMax has triumphed over Wickfire. On February 26, 2021, an Appellate Court issued a paramount ruling that Wickfire lacked any evidence to support its claims against TriMax. The decision was made in the United States Court of Appeals for the Fifth Circuit, Case Number 17-3043040. The Appellate Court’s ruling reversed all monetary damages previously awarded to Wickfire. The lawsuit, originally before the Western District of Texas, Case No. 14-CV-34, centered around Google AdWords Auctions, an online-auction platform where companies like TriMax and Wickfire compete for advertising space. Wickfire asserted innumerable claims against TriMax, but as to each one, Wickfire ultimately faile

Informa Markets Drives Economic Recovery with Safe and Successful Return to the Show Floor4.3.2021 20:52:58 CET | Press release

Informa Markets makes a customer-driven return to live events, driving economic recovery, connection and innovation through a collaborative and foundational approach to safety ORLANDO, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- As industries and economies around the world look for opportunities to rebuild business in the wake of the COVID-19 pandemic, Informa Markets, a global organizer who creates platforms for a wide range of industries to trade, connect and grow, launched MAGIC Pop-Up Orlando from February 9-11 at the Orange County Convention Center. The ‘Pop-Up’, a smaller scale regional version of their keystone fashion event which typically takes place twice-yearly in Las Vegas, Nevada was a comprehensive ‘one-stop-shop’ opportunity for various segments of the fashion industry, one of the many industries hit hard by the pandemic’s devastating economic impact, to discover new brands, safely network with like-minded retailers, and generate much-needed revenue. Informa Markets Fashion

CoinShares announces outcome of offering in connection with its intended listing on Nasdaq First North Growth Market4.3.2021 20:30:00 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Saint Helier, JERSEY, 4 March, 2021 The subscription period for shares in the initial public offering (the “Offering”) from CoinShares International Limited (“CoinShares” or the “Company”) ended Tuesday, 2 March, 2021. The outcome of the Offering shows that the Offering was subscribed to 447% and that the Company will receive proceeds of SEK 151.1 million before issue costs. The Offering of SEK 151.1 million was covered by subscription commitments of SEK 125.5 million, corresponding to 83% of the total